A Phase 1 Study to Evaluate the Safety and Dosimetry of [68Ga]-NOTA-hGZP (CSB-111) PET Imaging in Healthy Human Volunteers.
Latest Information Update: 11 Aug 2023
At a glance
- Drugs Gallium-68 NOTA hGZP (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer
- Focus Diagnostic use; Pharmacokinetics
- Sponsors Cytosite Bio
- 19 May 2023 Status changed from recruiting to completed.
- 25 Nov 2022 Planned End Date changed from 15 Dec 2022 to 15 Dec 2023.
- 25 Nov 2022 Planned primary completion date changed from 15 Nov 2022 to 15 Mar 2023.